Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases.
Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe.
The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer.
Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.
If you think you have the same passion and commitment we have, check out www.radiuspharm.com.
- Company Name:Radius Health, Inc.
(View Trends)
-
Headquarters: (View Map)Waltham, MA, United States
-
Pharmaceuticals
-
200 - 500 employees
- 2517655 Global Rank
- 502910 United States
-
Search54.83%
-
Direct42.13%
-
Mail1.66%
-
Referrals1.38%
-
Display0.00%
-
Social0.00%
- United States 71.0%
- Canada 13.2%
- India 5.8%
- Philippines 1.1%
- Français
- Actualité
- Journaux
-
Standard100.00%
They are headquartered at Waltham, MA, United States, and have 5 advertising & marketing contacts listed on Kochava. Radius Health, Inc. works with Advertising technology companies such as ExactTarget, DoubleClick.Net.